Current Frontline Treatment of Diffuse Large B-Cell Lymphoma.

MA Spinner, RH Advani - Oncology (08909091), 2022 - search.ebscohost.com
Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin
lymphoma, is an aggressive and biologically heterogeneous disease. Risk stratifi cation and …
被引用次数：21 相关文章

Current Frontline Treatment of Diffuse Large B-Cell Lymphoma

MA Spinner, RH Advani - Oncology (Williston Park, NY), 2022 - pubmed.ncbi.nlm.nih.gov
Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin
lymphoma, is an aggressive and biologically heterogeneous disease. Risk stratification and …

Current Frontline Treatment of Diffuse Large B-Cell Lymphoma

Oncology, 2022 - search.proquest.com
DLBCL, diffuse large B-cell lymphoma, non-Hodgkin lymphoma, R-CHOP, pola-R-CHP
Introduction Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non …

Current Frontline Treatment of Diffuse Large B-Cell Lymphoma.

MA Spinner, RH Advani - Oncology (Williston Park, NY), 2022 - europepmc.org
Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin
lymphoma, is an aggressive and biologically heterogeneous disease. Risk stratification and …